APA (7th ed.) Citation

GM, C., GB, A., S, A., S, B., GA, B., AB, C., . . . PE, P. (2021). Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. American journal of nephrology, 52(3), 180. https://doi.org/10.1159/000513777

Chicago Style (17th ed.) Citation

GM, Chertow, et al. "Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome." American Journal of Nephrology 52, no. 3 (2021): 180. https://doi.org/10.1159/000513777.

MLA (9th ed.) Citation

GM, Chertow, et al. "Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome." American Journal of Nephrology, vol. 52, no. 3, 2021, p. 180, https://doi.org/10.1159/000513777.